Lusutrombopag to help platelet recovery after allogeneic stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an investigator-initiated, prospective, single-center, open-label trial testing lusutrombopag given after HLA haploidentical allogeneic hematopoietic stem cell transplantation to promote platelet remodeling. Adult patients with hematologic disorders who meet performance and organ-function criteria will receive oral lusutrombopag and undergo regular monitoring of platelet counts and adverse events. The trial will primarily look at platelet recovery dynamics and safety signals such as bleeding, thrombotic events, and other drug-related adverse effects. Findings will inform whether lusutrombopag can shorten time to stable platelet counts and reduce transfusion needs in this transplant population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Participants must meet the following criteria:

1. The patient signed an informed consent form and voluntarily participated in the study.
2. Patients undergoing HLA haploidentical allogeneic hematopoietic stem cell transplantation;
3. Age ≥18 years, regardless of gender
4. ECOG score 0-2
5. Expected survival ≥3 months
6. No severe impairment of function of major organs

Exclusion Criteria:

If any of the following criteria are met, the participants must be excluded from this research project:

1\) Patients with known allergy to TPO-RAs; 2) Patients who cannot take oral medication due to gastrointestinal symptoms, altered mental status, etc. during transplantation; 3) Other reasons for exclusion as determined by the investigator.

\-

Where it's running

• The General Hospital of the People's Liberation Army
  Chengdu, China Recruiting

Study contacts

• Study coordinator: Lei Ma
• Email: 408955783@qq.com
• Phone: +8615680600612

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Second or greater stem cell transplant using reduced intensity conditioning

  This study is testing a gentler approach to give a second or more stem cell transplant to patients with blood disorders who didn't get enough benefit from their first transplant to see if it helps them recover better.

  Recruiting Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT01666080

• HSCT outcomes in children at Ramathibodi Hospital

  This study tests how hematopoietic stem cell transplantation works in pediatric patients with blood diseases, cancers, and other conditions at Ramathibodi Hospital.

  Recruiting Mahidol University · Ratchathewi, Bangkok · NCT07857746

• Reconstruction kinetics of γδ T cells after an unrelated cord blood transplant

  This study tests how γδ T cells recover after an unrelated cord blood transplant and whether recovery patterns relate to outcomes like graft-versus-host disease, relapse, and survival.

  Recruiting Anhui Provincial Hospital · Hefei, Anhui · NCT07782684

• Clonal haematopoiesis assessment and long-term monitoring for prevention and care

  This project will follow people aged 55 and older who have clonal haematopoiesis or unexplained low blood counts to see how their blood changes over time and whether they develop heart disease or blood cancers.

  Recruiting Clinical Hub for Interventional Research (CHOIR) · Canberra, Australian Capital Territory · NCT07313059

• KLN-1010 gene therapy for relapsed or refractory multiple myeloma

  This Phase 1 trial will try KLN-1010, an in vivo CAR‑T gene therapy, to see if it is safe and can be given at a tolerable dose for people with relapsed or refractory multiple myeloma who have had at least three prior therapies.

  Recruiting at 11 sites Phase 1 Kelonia Therapeutics, Inc. · Duarte, California and 10 other locations · NCT07075185

• Early tacrolimus in HLA-mismatched haploidentical blood stem-cell transplant with post-transplant cyclophosphamide

  This trial tests whether starting tacrolimus earlier, together with post-transplant cyclophosphamide and mycophenolate, can reduce cytokine release syndrome in people receiving HLA-mismatched haploidentical peripheral blood stem-cell transplants.

  Recruiting Phase 2 Northside Hospital, Inc. · Atlanta, Georgia · NCT06828796

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.